Clinical  Hepatology Debrief
AASLD LiverLearning®, Kris Kowdley, 202145
Clinical  Hepatology Debrief
AASLD LiverLearning®, Michael Fried, 202146
NAFLD Debrief
AASLD LiverLearning®, Kymberly Watt, 202143
NAFLD Debrief
AASLD LiverLearning®, Michael Fried, 202144
Hepatitis Debrief
AASLD LiverLearning®, Paul Kwo, 202141
Hepatitis Debrief
AASLD LiverLearning®, Michael Fried, 202142
Leon Schiff SOA: Acute on Chronic Liver Failure
AASLD LiverLearning®, Patrick Kamath, 202139
Leon Schiff SOA: Acute on Chronic Liver Failure
AASLD LiverLearning®, Guadalupe Garcia-Tsao, 202140
Mayo Spheroid Reservoir Bio-Artificial Liver Improves Survival and Promotes Liver Regeneration in Post Hepatectomy ALF Pigs
AASLD LiverLearning®, Harvey Chen, 201444
Chemical and Toxicology Analysis of Ayurvedic and Herbal Drugs Causing Severe Liver Injury
AASLD LiverLearning®, Cyriac Philips, 201445
Evaluation of spheroid reservoir bioartificial liver with porcine hepatocytes in rhesus monkey model of acute liver failure
AASLD LiverLearning®, YI LI, 201446
Development of a new inhibitory antibody for prevention of HCV infection
AASLD LiverLearning®, Ken Okai, 201447
Human stem cell-derived Encapsulated Mature Liver Tissue as an effective, consistent, and durable in vitro tool for drug testing and development
AASLD LiverLearning®, Massimiliano Paganelli, 201448
The Frequency of Herbal and Dietary Supplement Mislabeling: Experience of the Drug Induced Liver Injury Network
AASLD LiverLearning®, Victor Navarro, 201449
HCV Patient Populations With Challenging Treatment Decisions
AASLD LiverLearning®, Paul Pockros, 202138
Ultrasound-based Elastography for NAFLD
AASLD LiverLearning®, Laurent Castera, 202132
New HCV Therapies in 2017 and Their Impact on Treatment Strategies
AASLD LiverLearning®, Paul Kwo, 202137
Global Perspectives on HCV Eradication
AASLD LiverLearning®, Philippa Easterbrook, 202136
Magnetic Resonance Elastography for NAFLD
AASLD LiverLearning®, Rohit Loomba, 202131
"From the AASLD-IDSA Guidance Committee: How We Make Our Recommendations, What Important Gaps Remain in the Care of HCV Patients?"
AASLD LiverLearning®, Susanna Naggie, 202135
Program Chair
AASLD LiverLearning®, Andrew Muir, 202133
Program Chair
AASLD LiverLearning®, Donald Jensen, 202134
Assessing Severity of Portal Hypertension and Prognosis
AASLD LiverLearning®, Massimo Pinzani, 202130
How Accurate is the Diagnosis of Cirrhosis?
AASLD LiverLearning®, Sumeet Asrani, 202129
Program Chair
AASLD LiverLearning®, Jayant Talwalkar, 202127
Program Chair
AASLD LiverLearning®, Laurent Castera, 202128
Closing Remarks
AASLD LiverLearning®, Zobair Younossi, 202124
NAFLD in Children: A Global Perspective
AASLD LiverLearning®, Miriam Vos, 202123
African Content Perspective – AFASLD
AASLD LiverLearning®, Ibrahim Mostafa, 202122
South American Perspective – ALEH
AASLD LiverLearning®, Marco Arrese, 202121
Asia-Pacific Perspective – APASL
AASLD LiverLearning®, Barjesh Sharma, 202120
European Perspective – EASL
AASLD LiverLearning®, Frank Tacke, 202119
Hans Popper Basic Science SOA: Gut Microbiota and Liver
AASLD LiverLearning®, Bernd Schnabl, 202125
Hans Popper Basic Science SOA: Gut Microbiota and Liver
AASLD LiverLearning®, Gavin Arteel, 202126
Program Chair
AASLD LiverLearning®, Zobair Younossi, 202116
Program Chair
AASLD LiverLearning®, Miriam Vos, 202117
North American Perspective – AASLD
AASLD LiverLearning®, Zobair Younossi, 202118
Should Patients with HCV Early Stage & HCC Receive Concomitant Therapy?
AASLD LiverLearning®, Laura Kulik, 202110
New Treatment Algorithm for Management of Autoimmune Hepatitis
AASLD LiverLearning®, John Vierling, 202115
Do DAA Therapies for HCV Increase HCC Recurrence: No?
AASLD LiverLearning®, Amit Singal, 202109
New Strategies for Diagnosis and Surveillance of Cholangiocarcinoma in PSC
AASLD LiverLearning®, Christoph Schramm, 202114
Session II Moderator
AASLD LiverLearning®, Hashem El-Serag, 202106
Session II Moderator
AASLD LiverLearning®, Laura Kulik, 202107
Do DAA Therapies for HCV increase HCC Recurrence: Yes?
AASLD LiverLearning®, Maria Elisa Reig, 202108
Session I Moderator
AASLD LiverLearning®, Cynthia Levy, 202111
Session I Moderator
AASLD LiverLearning®, Elizabeth Carey, 202112
Advances in the Management of PBC
AASLD LiverLearning®, Christopher Bowlus, 202113
Do DAA Therapies for HCV Increase HCC Recurrence Following Liver Transplantation: Yes?
AASLD LiverLearning®, Michael Leise, 202105
Program Chair
AASLD LiverLearning®, Gregory Gores, 202100
Session I Moderator
AASLD LiverLearning®, Maria Elisa Reig, 202101
Session I Moderator
AASLD LiverLearning®, Augusto Villanueva, 202102
HCV SVR and HCC Incidence: Interferon Era
AASLD LiverLearning®, Hashem El-Serag, 202103
Hyman J. Zimmerman Hepatotoxicity SOA: Assessing DILI Risk in the Life Cycle of Drugs and Biologics: A Challenge for Regulatory Science
AASLD LiverLearning®, Mark Avigan, 202098
Hyman J. Zimmerman Hepatotoxicity SOA: Assessing DILI Risk in the Life Cycle of Drugs and Biologics: A Challenge for Regulatory Science
AASLD LiverLearning®, Robert Fontana, 202099
Clincal Educator/Mentor Award (DCEMA)
AASLD LiverLearning®, Session Speakers, 202097
AASLD Distinguished Service Award (DSA)
AASLD LiverLearning®, Session Speakers, 202096
AASLD Distinguished Achievement Award (DAA)
AASLD LiverLearning®, Session Speakers, 202095
Metagenomic analysis shows a shift in taxonomic and functional composition of the gut microbiota in NASH patients
AASLD LiverLearning®, Jerome Boursier, 195709
A National Survey of Physicians Regarding Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH): The Disease and Clinical Trial Awareness Program for NASH
AASLD LiverLearning®, Zobair Younossi, 195775
Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis
AASLD LiverLearning®, Stephen Harrison, 195660
The Impact Of Obeticholic Acid (OCA) On Atherogenic Lipoproteins In Nonalcoholic Steatohepatitis
AASLD LiverLearning®, Arun Sanyal, 195688
Disruption of hepatic IL-1 signaling improves insulin sensitivity and hepatic inflammation in a model of non-alcoholic fatty liver disease (NAFLD).
AASLD LiverLearning®, Nadine Gehrke, 195524
Lipoprotein sub-fractions show increased cardiovascular disease risk in pediatric non-alcoholic steatohepatitis compared to non-alcoholic fatty liver
AASLD LiverLearning®, Juna Konomi, 195634
Evaluating the Response to Placebo in Randomized Controlled Trials of Nonalcoholic Steatohepatitis: A systematic review and meta-analysis
AASLD LiverLearning®, Ma Ai Thanda Han, 195675
NGM282 Ameliorates Hepatic Lipotoxicity as Measured by Lipidomics and Gene Expression in a Diet-Induced Mouse Model of Nonalcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Lei Ling, 195548
Cross talk between Sirtuins and TGF-β signaling - new models for non alcoholic steatohepatitis and progression to HCC
AASLD LiverLearning®, Lopa Mishra, 195531
Beneficial effects of combined farnesoid X receptor agonist (INT747) and dipeptidyl peptidase-4 inhibitor (sitagliptin) on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
AASLD LiverLearning®, Naotaka Shimozato, 195540
Utilization of palliative care in patients with cirrhosis
AASLD LiverLearning®, Mohsen Pourmorteza, 195342
The effect of Aramchol on fibrosis is mediated by elevation of glutathione, improvement of fatty acid oxidation and maintenance of redox homeostasis
AASLD LiverLearning®, Jose Mato, 195598
MYC is the master switch between tumor dormancy and relapse in Hepatocellular carcinoma (HCC)
AASLD LiverLearning®, Renumathy Dhanasekaran, 195358
GPBAR1 (TGR5) is a positive regulator of autophagy in response to fast-to-fed transition and its activation improves lipid metabolism in mice feed a high fat diet
AASLD LiverLearning®, Fiorucci Stefano, 195614
MAGE-1-targeting Aptamer Inhibits Hepatocellular Carcinoma Cell Growth via Suppression of PFKFB4 Expression
AASLD LiverLearning®, Yun Bin Lee, 195374
Low Level Palmitate Acid Mediates an Adaptive Mitochondrial Homeostasis Against the Hepatotoxicity Induced by High Level Palmitate Acid or CCL4---A Little Bad Fat Is Good
AASLD LiverLearning®, Lin Liu, 195630
The novel tumor suppressor Trefoil Factor Family 1 (TFF1) inhibits the development of hepatocellular carcinoma in mice
AASLD LiverLearning®, Junpei Yamaguchi, 195390
Non-invasive stratification of fatty liver disease with high-throughput multiparametric MRI
AASLD LiverLearning®, Matt Kelly, 195646
A multicenter study revealing chronic hepatitis B comorbidity trends over the last 15 years in the United States
AASLD LiverLearning®, Anne Liu, 195406
Prevalence of liver fibrosis as defined by non-invasive markers in non-HBV Chinese general population with Normal ALT: a large population study
AASLD LiverLearning®, Rong Yu, 195662
Changes of Serum Pregenomic RNA, Quantitative Anti-HBc and Intrahepatic Covalently Closed Circular DNA during Treatment of Chronic Hepatitis B
AASLD LiverLearning®, Xiaomei Wang, 195422
Screening for therapeutic trials, treatment indication in clinical practice: a new blood test to diagnose fibrotic NASH
AASLD LiverLearning®, Jerome Boursier, 195678
A dynamic change in Albumin-Bilirubin grade can effectively stratify patient’s risk for developing hepatocellular carcinoma for patients treated with entecavir
AASLD LiverLearning®, Jungyoon Kim, 195438
Early body weight reduction after the administration of SGLT-2 inhibitor is an independent factor contributed to rapid improvement of NAFLD
AASLD LiverLearning®, Takamasa Ohki, 195694
HBsAg and HBcrAg as predictors of seroconversion in a pan-genotypic population of hepatitis B e antigen positive patients treated with nucleos(t)ide analogues
AASLD LiverLearning®, Bo Wang, 195454
Evaluation of the safety, pharmacokinetics, and pharmacodynamic effects on de novo lipogenesis of the acetyl-CoA carboxylase inhibitor GS-0976 in healthy volunteers
AASLD LiverLearning®, Brian Kirby, 195710
Non-invasive diagnosis of significant fibrosis in antiviral-naive chronic HBV infection could be improved by using the novel GP73-LS algorithm
AASLD LiverLearning®, ZhuJun Cao, 195470
Body composition and muscle fitness associate with nonalcoholic fatty liver disease (NAFLD)
AASLD LiverLearning®, Vincent Chen, 195726
High Prevalence of Probable NAFLD and Advanced Fibrosis in a Population of Type II Diabetes Patients Followed by Endocrinology and Primary Care
AASLD LiverLearning®, Kartik Joshi, 195729
Ammonia withdrawal reverses impaired skeletal muscle mitochondrial function.
AASLD LiverLearning®, Srinivasan Dasarathy, 195486
Correlation of mammographic fat infiltrated axillary lymph nodes with non-alcoholic fatty liver disease
AASLD LiverLearning®, Natalie Ring, 195745
Nox1 as a Novel Source of Hepatic Oxidant Stress during Obesity to Promote Lipotoxicity in Humans and Mice with Non-alcoholic Fatty Liver Disease
AASLD LiverLearning®, Sebastian Larion, 195502
Involvement of 1-deoxy-sphinglolipids in steatogenesis in Non Alcoholic Fatty Liver Disease
AASLD LiverLearning®, Jonas Weyler, 195761
Deficiency of cholesterol 7α hydroxylase (Cyp7a1) in bile acid synthesis exacerbates alcohol-induced liver injury in mice
AASLD LiverLearning®, Ajay Donepudi, 195518
No differences in Physiological Response during Cardiopulmonary Exercise Testing in Patients with and without Non-alcoholic Fatty Liver Disease
AASLD LiverLearning®, Zobair Younossi, 195777
Fatty acid synthase inhibitor TVB-3664 reduces collagen accumulation in bleomycin-induced murine skin fibrosis and reverses multiple components of diet-induced and biopsy-confirmed nonalcoholic steatohepatitis in mice treated with or without co-administer
AASLD LiverLearning®, Gregory Duke, 195534
Inhibition of HDAC6 and autophagy reverts ciliary loss and decreases proliferation rates in cholangiocarcinoma cells
AASLD LiverLearning®, Estanislao Peixoto, 195294
CB4209 and CB4211 Reduce the NAFLD Activity Score in the STAM Model of NASH, Reduce Triglyceride Levels, and Induce Selective Fat Mass Loss in DIO Mice
AASLD LiverLearning®, Kenneth Cundy, 195550
Changing Expression Profiles of lncRNAs, mRNAs, circRNAs and miRNAs in Biliary Epithelial Cells after Bile Acid (TDCA) Stimulation
AASLD LiverLearning®, Eric Gershwin, 195295
Exposure to gulf war illness-related chemicals increases susceptibility to cholestatic liver injury by enhancing CD11b+ macrophage/monocyte infiltration into the liver
AASLD LiverLearning®, Jessica Kain, 195310
Altered liver methylome and transcriptome provide evidence for epigenetic contribution to NAFLD pathogenesis
AASLD LiverLearning®, Lixin Zhu, 195566
Baseline Serum Creatinine and Delta Creatinine Predict Persistent Acute Kidney Injury in Outpatient Cirrhotics
AASLD LiverLearning®, Giuseppe Cullaro, 195326
Chronic Polychlorinated Biphenyl (PCB) Exposure Disrupts Hepatic Xenobiotic and Intermediary Metabolism and Increases Hepatic Inflammation/Injury
AASLD LiverLearning®, Hongxue Shi, 195582